BRACANALYSIS CDX

Cancer-related Germline Gene Mutation Detection System

FDA Premarket Approval P140020

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the bracanalysis cdx. This device is indicated as follows: bracanalysis cdx is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the brca1 and brca2 genes using genomic dna obtained from whole blood specimens collected in edta. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (pcr) and sanger sequencing. Large deletions and duplications in brca1 and brca2 are detected using multiplex pcr. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline brca variants eligible for treatment with lynparza (olaparib). This assay is for professional use only and is to be performed only at myriad genetic laboratories, a single laboratory site located at 320 wakara way, salt lake city, ut 84108.

DeviceBRACANALYSIS CDX
Classification NameCancer-related Germline Gene Mutation Detection System
Generic NameCancer-related Germline Gene Mutation Detection System
ApplicantMYRIAD GENETIC LABORATORIES
Date Received2014-09-24
Decision Date2014-12-19
Notice Date2014-12-30
PMAP140020
SupplementS
Product CodePJG
Docket Number14M-2248
Advisory CommitteePathology
Expedited ReviewYes
Combination Product No
Applicant Address MYRIAD GENETIC LABORATORIES 320 Wakara Way salt Lake City, UT 84108
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P140020Original Filing
S026 2023-01-11 30-day Notice
S025 2022-10-18 Special (immediate Track)
S024 2022-10-14 30-day Notice
S023
S022 2021-10-22 Normal 180 Day Track
S021 2021-06-04 30-day Notice
S020 2019-12-06 Normal 180 Day Track
S019 2019-07-02 Normal 180 Day Track
S018 2018-09-21 Normal 180 Day Track
S017 2018-07-31 Real-time Process
S016 2018-06-29 Normal 180 Day Track
S015 2018-04-09 Normal 180 Day Track
S014 2018-03-22 Normal 180 Day Track
S013 2017-09-29 30-day Notice
S012 2017-08-31 Normal 180 Day Track
S011
S010
S009 2016-12-20 Normal 180 Day Track
S008 2016-10-27 Normal 180 Day Track
S007 2016-06-07 Real-time Process
S006 2016-03-23 Real-time Process
S005 2015-01-21 30-day Notice
S004 2015-11-25 30-day Notice
S003 2015-09-17 Real-time Process
S002 2015-07-22 Real-time Process
S001 2015-06-19 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.